mRNA Therapy Market Analysis, Size, Share & Growth Forecast 2026–2034

COVID-19 mRNA Vaccine Success Demonstrating Sequence-to-Emergency-Authorisation in Under 12 Months at Global Scale Has Validated the mRNA Platform Speed, Scalability, and Immunogenicity That Is Now Being Applied to Cancer Neoantigen, RSV, and Rare Disease Programmes.Moderna and Merck's mRNA-4157 KEYNOTE-942 Phase 2b demonstrated 49% reduction versus pembrolizumab alone in KEYNOTE-942 across 157 high-risk resected Stage III-IV melanoma patients, and the Phase 3 KEYNOTE-V940 programme enrolling 1,000 patients is the definitive test that will determine whether personalised neoantigen vaccination achieves regulatory approval. The manufacturing workflow involves tumour whole-exome sequencing, computational neoantigen ranking using MHC-binding affinity prediction, synthesis of up to 34 personalised neoantigen-encoding mRNA sequences, and formulation in lipid nanoparticle for subcutaneous injection within a 45-day cycle. The commercial pricing model for personalised mRNA cancer vaccines is expected to exceed USD 100,000 per patient based on manufacturing complexity and demonstrated survival benefit, creating value-based pricing justification that available frameworks for personalised oncology therapy support if Phase 3 data confirms the Phase 2 efficacy signal.

Personalised mRNA Cancer Neoantigen Vaccine Using Tumour Sequencing, AI Neoantigen Prioritisation, and Individual mRNA Synthesis Is Demonstrating the Individualised Immunotherapy Approach That Moderna and BioNTech Are Evaluating in Adjuvant Melanoma.Moderna's mRNA-1010 quadrivalent influenza vaccine Phase 3 data demonstrating non-inferior immunogenicity to comparator vaccines and superiority for two of four strains supports development toward a commercial seasonal influenza vaccine updating mRNA sequence within weeks of WHO strain recommendation rather than the 6-month egg manufacturing cycle. The manufacturing speed advantage is the most significant platform differentiation from egg-based vaccines, and the mRNA-influenza programme targets the strain-mismatch seasons where conventional vaccine effectiveness falls to 20-40%. Pfizer and BioNTech's RSV mRNA clinical programme and Moderna's mRNA-1345 RSV vaccine demonstrating competitive non-inferior efficacy data to protein subunit RSV vaccines confirm that mRNA platforms achieve comparable RSV immunogenicity at potentially simpler manufacturing scale.

Self-Amplifying RNA Using Alphavirus Replicon Intracellular Amplification to Produce Larger Protein Expression From Smaller Delivered Dose Is Reducing the LNP Quantity Per Dose and the Manufacturing Cost That Conventional Non-Replicating mRNA Immunisation Requires.Moderna's mRNA-3705 methylmalonyl-CoA mutase mRNA and mRNA-3927 PCCA mRNA delivered in lipid nanoparticles to the liver demonstrate hepatic enzyme expression for 10-14 days per dose, achieving metabolite normalisation that enzyme replacement therapy cannot accomplish due to insufficient hepatic uptake from systemic circulation. The clinical challenge for therapeutic mRNA in metabolic disease is immunogenicity of repeated dosing where adaptive immune responses to LNP components or mRNA-expressed protein can reduce efficacy over time, and modified nucleoside incorporation including N1-methyl pseudouridine partially reduces innate immune activation that limits durability. The regulatory pathway for mRNA therapeutics in rare metabolic disease is being defined through FDA breakthrough therapy designation programmes accommodating the limited patient populations where rare metabolic conditions enable accelerated approval based on biomarker endpoints.

For related market intelligence, see the Mrna Vaccine Market.